{
    "info": {
        "nct_id": "NCT04409639",
        "official_title": "Phase 2 Trial of Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations",
        "inclusion_criteria": "* Male or female subject aged ≥ 18 years.\n* Newly diagnosed or hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML -0/-1/-2; 2016 WHO classification) with RAS pathway activation as determined by standard of care hematopoietic cell sequencing results on peripheral blood or bone marrow demonstrating NRAS, KRAS, PTPN11, FLT3, CBL, JAK2, BRAF or NF1 mutations at variant allele frequency ≥ 5%. BMBx, NGS, FISH or BCR-ABL1 PCR, and cytogenetics should be done at the primary trial site within 21 days prior to C1D1. 5.1.2 If the patient is FLT3-ITD positive, the FLT3-ITD PCR allelic ratio must be ≥ 0.05 on testing done on screening biopsy (NOTE: cannot quantitate FLT3-ITD VAF by NGS, must be a separate PCR test).\n* ECOG Performance Status ≤ 3.\n* Adequate organ function as defined as:\n\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)\n    * Unless elevation is related to Gilbert's syndrome, hemolysis, or thought to be due to leukemic hepatic involvement.\n    * AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN ----Unless elevation is related to leukemic hepatic involvement.\n  * Renal:\n\n    ---Serum creatinine ≤ 2x ULN\n  * OR\n\n    * Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula:\n    * Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)\n    * Females: (((140-age)×weight[kg])/(serum creatinine [mg/dL]×72))×0.85\n* Left ventricular function ≥ 50% as assessed by echocardiogram.\n* Negative pregnancy test for women of childbearing potential or evidence of post-menopausal status. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Highly effective contraception for both male and female subjects throughout the study and at least 3 months after the last dose of study therapy as described in Section 7.4 of the protocol.\n* Recovery to baseline or Grade ≤ 1 CTCAE v5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Previous exposure to experimental MEK inhibitors for CMML.\n* Grade 2 or greater QTc prolongation on screening electrocardiogram (ECG) or clinically significant cardiovascular disease (uncontrolled or symptomatic atrial arrhythmias, congestive heart failure, myocardial infarction/CABG/PCI within 6 months of screening, uncontrolled arterial hypertension or history of ventricular arrhythmia)\n* Clinical or laboratory evidence of central nervous system (CNS) leukemia.\n* Major surgery within 4 weeks prior to study drug initiation.\n* History of interstitial lung disease.\n* History of retinal detachment, central serous retinopathy (CSR), retinal vein occlusion (RVO), or at high risk for CSR or RVO following screening ophthalmologic exam at discretion of PI/Sub-I following review of exam findings, and, if necessary, consultation with ophthalmology provider.\n* Patients with muscular and/or neuromuscular disorders associated with elevated CPK (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, or spinal muscular atrophy).\n* Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment, (i.e. refractory nausea and vomiting, malabsorption and external biliary shunt).\n* Pregnant or nursing (lactating) women.\n* On chronic treatment with strong CYP3A inhibitors or patients taking St. John's Wort, carbamazepine, efavirenz, phenytoin, rifampin, and other strong and moderate CYP3A inducers.\n* Diagnosis of any other malignancy within 2 years before study enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or cervix, low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration), or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms, or any solid tumor malignancy that has been adequately treated for which there is no evidence of disease. Patients with monoclonal gammopathy of undetermined significance (MGUS) are permitted to enroll.\n* Known HIV infection with a detectable viral load at the time of screening.\n\n  --Note: Patients on effective antiretroviral therapy with an undetectable viral load at the time of screening are eligible for this trial.\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  --Note: Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Subjects taking prohibited medications as described in Section 6.3.2. A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur before the start of treatment.\n* Known prior severe hypersensitivity to cobimetinib or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Renal:",
                "criterions": [
                    {
                        "exact_snippets": "Renal:",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "criterion mentioned but no requirement specified"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Renal:",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "criterion mentioned but no requirement specified"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "---Serum creatinine ≤ 2x ULN",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 2x ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 2x ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* ECOG Performance Status ≤ 3.",
                "criterions": [
                    {
                        "exact_snippets": "ECOG Performance Status ≤ 3",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG Performance Status ≤ 3",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Unless elevation is related to Gilbert's syndrome, hemolysis, or thought to be due to leukemic hepatic involvement.",
                "criterions": [
                    {
                        "exact_snippets": "elevation is related to Gilbert's syndrome",
                        "criterion": "elevation",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "Gilbert's syndrome"
                        }
                    },
                    {
                        "exact_snippets": "elevation is related to ... hemolysis",
                        "criterion": "elevation",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "hemolysis"
                        }
                    },
                    {
                        "exact_snippets": "elevation is ... thought to be due to leukemic hepatic involvement",
                        "criterion": "elevation",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "leukemic hepatic involvement"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "elevation is related to Gilbert's syndrome",
                        "criterion": "elevation",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "Gilbert's syndrome"
                        }
                    },
                    {
                        "exact_snippets": "elevation is related to ... hemolysis",
                        "criterion": "elevation",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "hemolysis"
                        }
                    },
                    {
                        "exact_snippets": "elevation is ... thought to be due to leukemic hepatic involvement",
                        "criterion": "elevation",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "leukemic hepatic involvement"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)",
                "criterions": [
                    {
                        "exact_snippets": "Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x institutional upper limit of normal (ULN)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x institutional upper limit of normal (ULN)"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.",
                "criterions": [
                    {
                        "exact_snippets": "Able to provide informed consent",
                        "criterion": "informed consent capacity",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing to sign an approved consent form that conforms to federal and institutional guidelines",
                        "criterion": "consent form signing",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing to sign an approved consent form that conforms to federal and institutional guidelines",
                        "criterion": "consent form signing",
                        "requirement": {
                            "requirement_type": "form approval",
                            "expected_value": "conforms to federal and institutional guidelines"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to provide informed consent",
                        "criterion": "informed consent capacity",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "willing to sign an approved consent form that conforms to federal and institutional guidelines",
                                "criterion": "consent form signing",
                                "requirement": {
                                    "requirement_type": "willingness",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "willing to sign an approved consent form that conforms to federal and institutional guidelines",
                                "criterion": "consent form signing",
                                "requirement": {
                                    "requirement_type": "form approval",
                                    "expected_value": "conforms to federal and institutional guidelines"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Negative pregnancy test for women of childbearing potential or evidence of post-menopausal status. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:",
                "criterions": [
                    {
                        "exact_snippets": "Negative pregnancy test for women of childbearing potential",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "evidence of post-menopausal status ... amenorrheic for 12 months without an alternative medical cause",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    },
                    {
                        "exact_snippets": "evidence of post-menopausal status ... amenorrheic for 12 months without an alternative medical cause",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "evidence of post-menopausal status ... amenorrheic for 12 months without an alternative medical cause",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "alternative medical cause",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Negative pregnancy test for women of childbearing potential",
                                "criterion": "pregnancy status",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "negative"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "evidence of post-menopausal status ... amenorrheic for 12 months without an alternative medical cause",
                                "criterion": "menopausal status",
                                "requirement": {
                                    "requirement_type": "status",
                                    "expected_value": "post-menopausal"
                                }
                            },
                            {
                                "exact_snippets": "evidence of post-menopausal status ... amenorrheic for 12 months without an alternative medical cause",
                                "criterion": "menopausal status",
                                "requirement": {
                                    "requirement_type": "amenorrhea duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "evidence of post-menopausal status ... amenorrheic for 12 months without an alternative medical cause",
                                "criterion": "menopausal status",
                                "requirement": {
                                    "requirement_type": "alternative medical cause",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Females: (((140-age)×weight[kg])/(serum creatinine [mg/dL]×72))×0.85",
                "criterions": [
                    {
                        "exact_snippets": "Females: (((140-age)×weight[kg])/(serum creatinine [mg/dL]×72))×0.85",
                        "criterion": "female sex",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "used in creatinine clearance formula"
                        }
                    },
                    {
                        "exact_snippets": "weight[kg]",
                        "criterion": "weight",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "used in creatinine clearance formula"
                        }
                    },
                    {
                        "exact_snippets": "serum creatinine [mg/dL]",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "used in creatinine clearance formula"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Females: (((140-age)×weight[kg])/(serum creatinine [mg/dL]×72))×0.85",
                        "criterion": "female sex",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "used in creatinine clearance formula"
                        }
                    },
                    {
                        "exact_snippets": "weight[kg]",
                        "criterion": "weight",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "used in creatinine clearance formula"
                        }
                    },
                    {
                        "exact_snippets": "serum creatinine [mg/dL]",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "used in creatinine clearance formula"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                "criterions": [
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "weight",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "weight",
                        "requirement": {
                            "requirement_type": "unit",
                            "expected_value": "kg"
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "unit",
                            "expected_value": "mg/dL"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "weight",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "weight",
                        "requirement": {
                            "requirement_type": "unit",
                            "expected_value": "kg"
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "unit",
                            "expected_value": "mg/dL"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Recovery to baseline or Grade ≤ 1 CTCAE v5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Recovery to baseline or Grade ≤ 1 CTCAE v5.0 from toxicities related to any prior treatments",
                        "criterion": "toxicities related to any prior treatments",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE v5.0 grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Recovery to baseline or Grade ≤ 1 CTCAE v5.0 from toxicities related to any prior treatments",
                        "criterion": "toxicities related to any prior treatments",
                        "requirement": {
                            "requirement_type": "recovery_status",
                            "expected_value": "baseline"
                        }
                    },
                    {
                        "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                        "criterion": "adverse events (AEs)",
                        "requirement": {
                            "requirement_type": "clinical_significance",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                        "criterion": "adverse events (AEs)",
                        "requirement": {
                            "requirement_type": "stability_on_supportive_therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Recovery to baseline or Grade ≤ 1 CTCAE v5.0 from toxicities related to any prior treatments",
                                        "criterion": "toxicities related to any prior treatments",
                                        "requirement": {
                                            "requirement_type": "severity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 1,
                                                "unit": "CTCAE v5.0 grade"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Recovery to baseline or Grade ≤ 1 CTCAE v5.0 from toxicities related to any prior treatments",
                                        "criterion": "toxicities related to any prior treatments",
                                        "requirement": {
                                            "requirement_type": "recovery_status",
                                            "expected_value": "baseline"
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                                "criterion": "adverse events (AEs)",
                                "requirement": {
                                    "requirement_type": "clinical_significance",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                                "criterion": "adverse events (AEs)",
                                "requirement": {
                                    "requirement_type": "stability_on_supportive_therapy",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hepatic:",
                "criterions": [
                    {
                        "exact_snippets": "Hepatic:",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "criterion to be specified in subsequent text"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hepatic:",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "criterion to be specified in subsequent text"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* OR",
                "criterions": []
            },
            "logical_structure": {
                "or_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Adequate organ function as defined as:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* History of interstitial lung disease.",
                "criterions": [
                    {
                        "exact_snippets": "History of interstitial lung disease",
                        "criterion": "interstitial lung disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of interstitial lung disease",
                        "criterion": "interstitial lung disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of retinal detachment, central serous retinopathy (CSR), retinal vein occlusion (RVO), or at high risk for CSR or RVO following screening ophthalmologic exam at discretion of PI/Sub-I following review of exam findings, and, if necessary, consultation with ophthalmology provider.",
                "criterions": [
                    {
                        "exact_snippets": "History of retinal detachment",
                        "criterion": "retinal detachment",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "central serous retinopathy (CSR)",
                        "criterion": "central serous retinopathy (CSR)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "retinal vein occlusion (RVO)",
                        "criterion": "retinal vein occlusion (RVO)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at high risk for CSR or RVO following screening ophthalmologic exam",
                        "criterion": "risk for CSR or RVO",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "high"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of retinal detachment",
                        "criterion": "retinal detachment",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "central serous retinopathy (CSR)",
                        "criterion": "central serous retinopathy (CSR)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "retinal vein occlusion (RVO)",
                        "criterion": "retinal vein occlusion (RVO)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at high risk for CSR or RVO following screening ophthalmologic exam",
                        "criterion": "risk for CSR or RVO",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "high"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pregnant or nursing (lactating) women.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant ... women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "nursing (lactating) women",
                        "criterion": "nursing (lactating) status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnant ... women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "nursing (lactating) women",
                        "criterion": "nursing (lactating) status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Previous exposure to experimental MEK inhibitors for CMML.",
                "criterions": [
                    {
                        "exact_snippets": "Previous exposure to experimental MEK inhibitors for CMML.",
                        "criterion": "exposure to experimental MEK inhibitors for CMML",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Previous exposure to experimental MEK inhibitors for CMML.",
                    "criterion": "exposure to experimental MEK inhibitors for CMML",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Clinical or laboratory evidence of central nervous system (CNS) leukemia.",
                "criterions": [
                    {
                        "exact_snippets": "Clinical or laboratory evidence of central nervous system (CNS) leukemia",
                        "criterion": "central nervous system (CNS) leukemia",
                        "requirement": {
                            "requirement_type": "evidence (clinical or laboratory)",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Clinical or laboratory evidence of central nervous system (CNS) leukemia",
                    "criterion": "central nervous system (CNS) leukemia",
                    "requirement": {
                        "requirement_type": "evidence (clinical or laboratory)",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment, (i.e. refractory nausea and vomiting, malabsorption and external biliary shunt).",
                "criterions": [
                    {
                        "exact_snippets": "Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment",
                        "criterion": "gastrointestinal dysfunction",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment",
                        "criterion": "gastrointestinal dysfunction",
                        "requirement": {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment",
                        "criterion": "gastrointestinal dysfunction",
                        "requirement": {
                            "requirement_type": "interference with ability to swallow or absorb study treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "refractory nausea and vomiting",
                        "criterion": "refractory nausea and vomiting",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "malabsorption",
                        "criterion": "malabsorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "external biliary shunt",
                        "criterion": "external biliary shunt",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment",
                                "criterion": "gastrointestinal dysfunction",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment",
                                "criterion": "gastrointestinal dysfunction",
                                "requirement": {
                                    "requirement_type": "significance",
                                    "expected_value": "significant"
                                }
                            },
                            {
                                "exact_snippets": "Any active significant gastrointestinal dysfunction as determined by the clinical investigator to interfere with the patient's ability to swallow or absorb the study treatment",
                                "criterion": "gastrointestinal dysfunction",
                                "requirement": {
                                    "requirement_type": "interference with ability to swallow or absorb study treatment",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "refractory nausea and vomiting",
                        "criterion": "refractory nausea and vomiting",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "malabsorption",
                        "criterion": "malabsorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "external biliary shunt",
                        "criterion": "external biliary shunt",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.",
                "criterions": [
                    {
                        "exact_snippets": "Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice)",
                        "criterion": "active infection (including tuberculosis)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis B (known positive HBV surface antigen (HBsAg) result)",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "HBsAg status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice)",
                        "criterion": "active infection (including tuberculosis)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis B (known positive HBV surface antigen (HBsAg) result)",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "HBsAg status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Major surgery within 4 weeks prior to study drug initiation.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 4 weeks prior to study drug initiation.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Major surgery within 4 weeks prior to study drug initiation.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known HIV infection with a detectable viral load at the time of screening.",
                "criterions": [
                    {
                        "exact_snippets": "Known HIV infection",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "detectable viral load at the time of screening",
                        "criterion": "HIV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "detectable viral load at the time of screening",
                        "criterion": "HIV viral load",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known HIV infection",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "detectable viral load at the time of screening",
                                "criterion": "HIV viral load",
                                "requirement": {
                                    "requirement_type": "detectability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "detectable viral load at the time of screening",
                                "criterion": "HIV viral load",
                                "requirement": {
                                    "requirement_type": "timepoint",
                                    "expected_value": "at the time of screening"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known prior severe hypersensitivity to cobimetinib or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).",
                "criterions": [
                    {
                        "exact_snippets": "Known prior severe hypersensitivity to cobimetinib or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3)",
                        "criterion": "hypersensitivity to cobimetinib or any component in its formulations",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NCI CTCAE v5.0 Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Known prior severe hypersensitivity to cobimetinib or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3)",
                        "criterion": "hypersensitivity to cobimetinib or any component in its formulations",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known prior severe hypersensitivity to cobimetinib or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3)",
                        "criterion": "hypersensitivity to cobimetinib or any component in its formulations",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NCI CTCAE v5.0 Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Known prior severe hypersensitivity to cobimetinib or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3)",
                        "criterion": "hypersensitivity to cobimetinib or any component in its formulations",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Grade 2 or greater QTc prolongation on screening electrocardiogram (ECG) or clinically significant cardiovascular disease (uncontrolled or symptomatic atrial arrhythmias, congestive heart failure, myocardial infarction/CABG/PCI within 6 months of screening, uncontrolled arterial hypertension or history of ventricular arrhythmia)",
                "criterions": [
                    {
                        "exact_snippets": "Grade 2 or greater QTc prolongation on screening electrocardiogram (ECG)",
                        "criterion": "QTc prolongation",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Grade 2 or greater QTc prolongation on screening electrocardiogram (ECG)",
                        "criterion": "QTc prolongation",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "on screening electrocardiogram (ECG)"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant cardiovascular disease (uncontrolled or symptomatic atrial arrhythmias, congestive heart failure, myocardial infarction/CABG/PCI within 6 months of screening, uncontrolled arterial hypertension or history of ventricular arrhythmia)",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled or symptomatic atrial arrhythmias",
                        "criterion": "atrial arrhythmias",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled or symptomatic atrial arrhythmias",
                        "criterion": "atrial arrhythmias",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction/CABG/PCI within 6 months of screening",
                        "criterion": "myocardial infarction/CABG/PCI",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction/CABG/PCI within 6 months of screening",
                        "criterion": "myocardial infarction/CABG/PCI",
                        "requirement": {
                            "requirement_type": "relative_to",
                            "expected_value": "screening"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled arterial hypertension",
                        "criterion": "arterial hypertension",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "history of ventricular arrhythmia",
                        "criterion": "ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Grade 2 or greater QTc prolongation on screening electrocardiogram (ECG)",
                                "criterion": "QTc prolongation",
                                "requirement": {
                                    "requirement_type": "grade",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Grade 2 or greater QTc prolongation on screening electrocardiogram (ECG)",
                                "criterion": "QTc prolongation",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "on screening electrocardiogram (ECG)"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "clinically significant cardiovascular disease (uncontrolled or symptomatic atrial arrhythmias, congestive heart failure, myocardial infarction/CABG/PCI within 6 months of screening, uncontrolled arterial hypertension or history of ventricular arrhythmia)",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "uncontrolled or symptomatic atrial arrhythmias",
                                        "criterion": "atrial arrhythmias",
                                        "requirement": {
                                            "requirement_type": "control",
                                            "expected_value": "uncontrolled"
                                        }
                                    },
                                    {
                                        "exact_snippets": "uncontrolled or symptomatic atrial arrhythmias",
                                        "criterion": "atrial arrhythmias",
                                        "requirement": {
                                            "requirement_type": "symptomatic",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "congestive heart failure",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "myocardial infarction/CABG/PCI within 6 months of screening",
                                        "criterion": "myocardial infarction/CABG/PCI",
                                        "requirement": {
                                            "requirement_type": "timing",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "myocardial infarction/CABG/PCI within 6 months of screening",
                                        "criterion": "myocardial infarction/CABG/PCI",
                                        "requirement": {
                                            "requirement_type": "relative_to",
                                            "expected_value": "screening"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "uncontrolled arterial hypertension",
                                "criterion": "arterial hypertension",
                                "requirement": {
                                    "requirement_type": "control",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "history of ventricular arrhythmia",
                                "criterion": "ventricular arrhythmia",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Diagnosis of any other malignancy within 2 years before study enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or cervix, low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration), or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms, or any solid tumor malignancy that has been adequately treated for which there is no evidence of disease. Patients with monoclonal gammopathy of undetermined significance (MGUS) are permitted to enroll.",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis of any other malignancy within 2 years before study enrollment",
                        "criterion": "diagnosis of other malignancy",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of any other malignancy within 2 years before study enrollment",
                        "criterion": "diagnosis of other malignancy",
                        "requirement": {
                            "requirement_type": "timing relative to enrollment",
                            "expected_value": "before study enrollment"
                        }
                    },
                    {
                        "exact_snippets": "except for adequately treated basal cell or squamous cell skin cancer",
                        "criterion": "basal cell or squamous cell skin cancer",
                        "requirement": {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    },
                    {
                        "exact_snippets": "carcinoma in situ of the breast, bladder or cervix",
                        "criterion": "carcinoma in situ of the breast, bladder or cervix",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration)",
                        "criterion": "low-grade prostate cancer (Gleason 6 or below)",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "Gleason"
                            }
                        }
                    },
                    {
                        "exact_snippets": "low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration)",
                        "criterion": "low-grade prostate cancer (Gleason 6 or below)",
                        "requirement": {
                            "requirement_type": "management",
                            "expected_value": "on surveillance"
                        }
                    },
                    {
                        "exact_snippets": "low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration)",
                        "criterion": "low-grade prostate cancer (Gleason 6 or below)",
                        "requirement": {
                            "requirement_type": "treatment plan",
                            "expected_value": "no plans for treatment intervention"
                        }
                    },
                    {
                        "exact_snippets": "prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated with prostatectomy or radiotherapy"
                        }
                    },
                    {
                        "exact_snippets": "prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "current disease status",
                            "expected_value": "no evidence of disease"
                        }
                    },
                    {
                        "exact_snippets": "prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "current symptoms",
                            "expected_value": "no symptoms"
                        }
                    },
                    {
                        "exact_snippets": "any solid tumor malignancy that has been adequately treated for which there is no evidence of disease",
                        "criterion": "solid tumor malignancy",
                        "requirement": {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    },
                    {
                        "exact_snippets": "any solid tumor malignancy that has been adequately treated for which there is no evidence of disease",
                        "criterion": "solid tumor malignancy",
                        "requirement": {
                            "requirement_type": "current disease status",
                            "expected_value": "no evidence of disease"
                        }
                    },
                    {
                        "exact_snippets": "Patients with monoclonal gammopathy of undetermined significance (MGUS) are permitted to enroll",
                        "criterion": "monoclonal gammopathy of undetermined significance (MGUS)",
                        "requirement": {
                            "requirement_type": "enrollment permission",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Diagnosis of any other malignancy within 2 years before study enrollment",
                                        "criterion": "diagnosis of other malignancy",
                                        "requirement": {
                                            "requirement_type": "time since diagnosis",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 2,
                                                "unit": "years"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Diagnosis of any other malignancy within 2 years before study enrollment",
                                        "criterion": "diagnosis of other malignancy",
                                        "requirement": {
                                            "requirement_type": "timing relative to enrollment",
                                            "expected_value": "before study enrollment"
                                        }
                                    }
                                ]
                            },
                            {
                                "not_criteria": {
                                    "or_criteria": [
                                        {
                                            "exact_snippets": "except for adequately treated basal cell or squamous cell skin cancer",
                                            "criterion": "basal cell or squamous cell skin cancer",
                                            "requirement": {
                                                "requirement_type": "treatment adequacy",
                                                "expected_value": "adequately treated"
                                            }
                                        },
                                        {
                                            "exact_snippets": "carcinoma in situ of the breast, bladder or cervix",
                                            "criterion": "carcinoma in situ of the breast, bladder or cervix",
                                            "requirement": {
                                                "requirement_type": "presence",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "and_criteria": [
                                                {
                                                    "exact_snippets": "low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration)",
                                                    "criterion": "low-grade prostate cancer (Gleason 6 or below)",
                                                    "requirement": {
                                                        "requirement_type": "grade",
                                                        "expected_value": {
                                                            "operator": "<=",
                                                            "value": 6,
                                                            "unit": "Gleason"
                                                        }
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration)",
                                                    "criterion": "low-grade prostate cancer (Gleason 6 or below)",
                                                    "requirement": {
                                                        "requirement_type": "management",
                                                        "expected_value": "on surveillance"
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration)",
                                                    "criterion": "low-grade prostate cancer (Gleason 6 or below)",
                                                    "requirement": {
                                                        "requirement_type": "treatment plan",
                                                        "expected_value": "no plans for treatment intervention"
                                                    }
                                                }
                                            ]
                                        },
                                        {
                                            "and_criteria": [
                                                {
                                                    "exact_snippets": "prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms",
                                                    "criterion": "prostate cancer",
                                                    "requirement": {
                                                        "requirement_type": "treatment adequacy",
                                                        "expected_value": "adequately treated with prostatectomy or radiotherapy"
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms",
                                                    "criterion": "prostate cancer",
                                                    "requirement": {
                                                        "requirement_type": "current disease status",
                                                        "expected_value": "no evidence of disease"
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms",
                                                    "criterion": "prostate cancer",
                                                    "requirement": {
                                                        "requirement_type": "current symptoms",
                                                        "expected_value": "no symptoms"
                                                    }
                                                }
                                            ]
                                        },
                                        {
                                            "and_criteria": [
                                                {
                                                    "exact_snippets": "any solid tumor malignancy that has been adequately treated for which there is no evidence of disease",
                                                    "criterion": "solid tumor malignancy",
                                                    "requirement": {
                                                        "requirement_type": "treatment adequacy",
                                                        "expected_value": "adequately treated"
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "any solid tumor malignancy that has been adequately treated for which there is no evidence of disease",
                                                    "criterion": "solid tumor malignancy",
                                                    "requirement": {
                                                        "requirement_type": "current disease status",
                                                        "expected_value": "no evidence of disease"
                                                    }
                                                }
                                            ]
                                        },
                                        {
                                            "exact_snippets": "Patients with monoclonal gammopathy of undetermined significance (MGUS) are permitted to enroll",
                                            "criterion": "monoclonal gammopathy of undetermined significance (MGUS)",
                                            "requirement": {
                                                "requirement_type": "enrollment permission",
                                                "expected_value": true
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "--Note: Patients on effective antiretroviral therapy with an undetectable viral load at the time of screening are eligible for this trial.",
                "criterions": [
                    {
                        "exact_snippets": "Patients on effective antiretroviral therapy",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "undetectable viral load at the time of screening",
                        "criterion": "viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "undetectable viral load at the time of screening",
                        "criterion": "viral load",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Patients on effective antiretroviral therapy",
                                    "criterion": "antiretroviral therapy",
                                    "requirement": {
                                        "requirement_type": "effectiveness",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "undetectable viral load at the time of screening",
                                            "criterion": "viral load",
                                            "requirement": {
                                                "requirement_type": "detectability",
                                                "expected_value": false
                                            }
                                        },
                                        {
                                            "exact_snippets": "undetectable viral load at the time of screening",
                                            "criterion": "viral load",
                                            "requirement": {
                                                "requirement_type": "timepoint",
                                                "expected_value": "at the time of screening"
                                            }
                                        }
                                    ]
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.",
                "criterions": [
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to understand subject information",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to... give informed consent",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to give informed consent",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to... comply with the study protocol",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to comply with the study protocol",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to... complete the study",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to complete the study",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to understand subject information",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to... give informed consent",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to give informed consent",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to... comply with the study protocol",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to comply with the study protocol",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to... complete the study",
                        "criterion": "medical, psychiatric, cognitive, or other conditions",
                        "requirement": {
                            "requirement_type": "impact on ability to complete the study",
                            "expected_value": false
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Male or female subject aged ≥ 18 years.",
                "criterions": [
                    {
                        "exact_snippets": "Male or female subject",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "aged ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum_age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula:",
                "criterions": [
                    {
                        "exact_snippets": "Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula",
                        "criterion": "estimated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula",
                        "criterion": "estimated creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Estimated creatinine clearance \u001e 30 mL/min by Cockcroft-Gault formula",
                        "criterion": "estimated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated creatinine clearance \u001e 30 mL/min by Cockcroft-Gault formula",
                        "criterion": "estimated creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Left ventricular function ≥ 50% as assessed by echocardiogram.",
                "criterions": [
                    {
                        "exact_snippets": "Left ventricular function ≥ 50% as assessed by echocardiogram",
                        "criterion": "left ventricular function",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular function ≥ 50% as assessed by echocardiogram",
                        "criterion": "left ventricular function",
                        "requirement": {
                            "requirement_type": "assessment method",
                            "expected_value": "echocardiogram"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Left ventricular function  50% as assessed by echocardiogram",
                        "criterion": "left ventricular function",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular function  50% as assessed by echocardiogram",
                        "criterion": "left ventricular function",
                        "requirement": {
                            "requirement_type": "assessment method",
                            "expected_value": "echocardiogram"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Highly effective contraception for both male and female subjects throughout the study and at least 3 months after the last dose of study therapy as described in Section 7.4 of the protocol.",
                "criterions": [
                    {
                        "exact_snippets": "Highly effective contraception for both male and female subjects throughout the study and at least 3 months after the last dose of study therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "Highly effective contraception for both male and female subjects throughout the study and at least 3 months after the last dose of study therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": [
                                "male subjects",
                                "female subjects"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Highly effective contraception for both male and female subjects throughout the study and at least 3 months after the last dose of study therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "throughout the study and at least 3 months after the last dose of study therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN ----Unless elevation is related to leukemic hepatic involvement.",
                "criterions": [
                    {
                        "exact_snippets": "AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN",
                        "criterion": "AST (SGOT) and ALT (SGPT) levels",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "institutional ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Unless elevation is related to leukemic hepatic involvement",
                        "criterion": "elevation of AST/ALT due to leukemic hepatic involvement",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "not_criteria": {
                        "not_criteria": {
                            "exact_snippets": "Unless elevation is related to leukemic hepatic involvement",
                            "criterion": "elevation of AST/ALT due to leukemic hepatic involvement",
                            "requirement": {
                                "requirement_type": "exclusion",
                                "expected_value": true
                            }
                        }
                    }
                },
                "then_criteria": {
                    "exact_snippets": "AST(SGOT)/ALT(SGPT) \u00104 3 \r institutional ULN",
                    "criterion": "AST (SGOT) and ALT (SGPT) levels",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 3,
                                    "unit": "institutional ULN"
                                }
                            ]
                        }
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).",
                "criterions": [
                    {
                        "exact_snippets": "Women ≥50 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments",
                        "criterion": "amenorrhea duration after cessation of exogenous hormonal treatments",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments",
                        "criterion": "amenorrhea duration after cessation of exogenous hormonal treatments",
                        "requirement": {
                            "requirement_type": "cessation of exogenous hormonal treatments",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiation-induced menopause with last menses >1 year ago",
                        "criterion": "radiation-induced menopause",
                        "requirement": {
                            "requirement_type": "last menses",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "radiation-induced menopause with last menses >1 year ago",
                        "criterion": "radiation-induced menopause",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "radiation-induced"
                        }
                    },
                    {
                        "exact_snippets": "chemotherapy-induced menopause with last menses >1 year ago",
                        "criterion": "chemotherapy-induced menopause",
                        "requirement": {
                            "requirement_type": "last menses",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "chemotherapy-induced menopause with last menses >1 year ago",
                        "criterion": "chemotherapy-induced menopause",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "chemotherapy-induced"
                        }
                    },
                    {
                        "exact_snippets": "surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)",
                        "criterion": "surgical sterilization",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "bilateral oophorectomy",
                                "bilateral salpingectomy",
                                "hysterectomy"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Newly diagnosed or hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML -0/-1/-2; 2016 WHO classification) with RAS pathway activation as determined by standard of care hematopoietic cell sequencing results on peripheral blood or bone marrow demonstrating NRAS, KRAS, PTPN11, FLT3, CBL, JAK2, BRAF or NF1 mutations at variant allele frequency ≥ 5%. BMBx, NGS, FISH or BCR-ABL1 PCR, and cytogenetics should be done at the primary trial site within 21 days prior to C1D1. 5.1.2 If the patient is FLT3-ITD positive, the FLT3-ITD PCR allelic ratio must be ≥ 0.05 on testing done on screening biopsy (NOTE: cannot quantitate FLT3-ITD VAF by NGS, must be a separate PCR test).",
                "criterions": [
                    {
                        "exact_snippets": "Newly diagnosed or hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML -0/-1/-2; 2016 WHO classification)",
                        "criterion": "chronic myelomonocytic leukemia (CMML) diagnosis status",
                        "requirement": {
                            "requirement_type": "diagnosis status",
                            "expected_value": [
                                "newly diagnosed",
                                "HMA refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Newly diagnosed or hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML -0/-1/-2; 2016 WHO classification)",
                        "criterion": "chronic myelomonocytic leukemia (CMML) diagnosis status",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "CMML-0",
                                "CMML-1",
                                "CMML-2"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Newly diagnosed or hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML -0/-1/-2; 2016 WHO classification)",
                        "criterion": "chronic myelomonocytic leukemia (CMML) diagnosis status",
                        "requirement": {
                            "requirement_type": "classification system",
                            "expected_value": "2016 WHO classification"
                        }
                    },
                    {
                        "exact_snippets": "RAS pathway activation as determined by standard of care hematopoietic cell sequencing results on peripheral blood or bone marrow demonstrating NRAS, KRAS, PTPN11, FLT3, CBL, JAK2, BRAF or NF1 mutations at variant allele frequency ≥ 5%",
                        "criterion": "RAS pathway gene mutations",
                        "requirement": {
                            "requirement_type": "gene mutation",
                            "expected_value": [
                                "NRAS",
                                "KRAS",
                                "PTPN11",
                                "FLT3",
                                "CBL",
                                "JAK2",
                                "BRAF",
                                "NF1"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "RAS pathway activation as determined by standard of care hematopoietic cell sequencing results on peripheral blood or bone marrow demonstrating NRAS, KRAS, PTPN11, FLT3, CBL, JAK2, BRAF or NF1 mutations at variant allele frequency ≥ 5%",
                        "criterion": "RAS pathway gene mutations",
                        "requirement": {
                            "requirement_type": "variant allele frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "BMBx, NGS, FISH or BCR-ABL1 PCR, and cytogenetics should be done at the primary trial site within 21 days prior to C1D1",
                        "criterion": "molecular and cytogenetic testing at trial site",
                        "requirement": {
                            "requirement_type": "testing methods",
                            "expected_value": [
                                "BMBx",
                                "NGS",
                                "FISH",
                                "BCR-ABL1 PCR",
                                "cytogenetics"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "BMBx, NGS, FISH or BCR-ABL1 PCR, and cytogenetics should be done at the primary trial site within 21 days prior to C1D1",
                        "criterion": "molecular and cytogenetic testing at trial site",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "primary trial site"
                        }
                    },
                    {
                        "exact_snippets": "BMBx, NGS, FISH or BCR-ABL1 PCR, and cytogenetics should be done at the primary trial site within 21 days prior to C1D1",
                        "criterion": "molecular and cytogenetic testing at trial site",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to C1D1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "If the patient is FLT3-ITD positive, the FLT3-ITD PCR allelic ratio must be ≥ 0.05 on testing done on screening biopsy",
                        "criterion": "FLT3-ITD allelic ratio",
                        "requirement": {
                            "requirement_type": "FLT3-ITD status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "If the patient is FLT3-ITD positive, the FLT3-ITD PCR allelic ratio must be ≥ 0.05 on testing done on screening biopsy",
                        "criterion": "FLT3-ITD allelic ratio",
                        "requirement": {
                            "requirement_type": "allelic ratio",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.05,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "If the patient is FLT3-ITD positive, the FLT3-ITD PCR allelic ratio must be ≥ 0.05 on testing done on screening biopsy",
                        "criterion": "FLT3-ITD allelic ratio",
                        "requirement": {
                            "requirement_type": "testing method",
                            "expected_value": "PCR"
                        }
                    },
                    {
                        "exact_snippets": "If the patient is FLT3-ITD positive, the FLT3-ITD PCR allelic ratio must be ≥ 0.05 on testing done on screening biopsy",
                        "criterion": "FLT3-ITD allelic ratio",
                        "requirement": {
                            "requirement_type": "sample type",
                            "expected_value": "screening biopsy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).",
                "criterions": [
                    {
                        "exact_snippets": "Women <50 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Women <50 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "amenorrheic for 12 months or more following cessation of exogenous hormonal treatments",
                        "criterion": "amenorrhea duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "amenorrheic for 12 months or more following cessation of exogenous hormonal treatments",
                        "criterion": "amenorrhea duration",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "following cessation of exogenous hormonal treatments"
                        }
                    },
                    {
                        "exact_snippets": "luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution",
                        "criterion": "luteinizing hormone and follicle-stimulating hormone levels",
                        "requirement": {
                            "requirement_type": "level",
                            "expected_value": "in the post-menopausal range for the institution"
                        }
                    },
                    {
                        "exact_snippets": "surgical sterilization (bilateral oophorectomy or hysterectomy)",
                        "criterion": "surgical sterilization",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "bilateral oophorectomy",
                                "hysterectomy"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* On chronic treatment with strong CYP3A inhibitors or patients taking St. John's Wort, carbamazepine, efavirenz, phenytoin, rifampin, and other strong and moderate CYP3A inducers.",
                "criterions": [
                    {
                        "exact_snippets": "On chronic treatment with strong CYP3A inhibitors",
                        "criterion": "chronic treatment with strong CYP3A inhibitors",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients taking St. John's Wort, carbamazepine, efavirenz, phenytoin, rifampin, and other strong and moderate CYP3A inducers",
                        "criterion": "use of strong or moderate CYP3A inducers",
                        "requirement": {
                            "requirement_type": "drug use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients taking St. John's Wort, carbamazepine, efavirenz, phenytoin, rifampin, and other strong and moderate CYP3A inducers",
                        "criterion": "use of strong or moderate CYP3A inducers",
                        "requirement": {
                            "requirement_type": "drug list",
                            "expected_value": [
                                "St. John's Wort",
                                "carbamazepine",
                                "efavirenz",
                                "phenytoin",
                                "rifampin"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Subjects taking prohibited medications as described in Section 6.3.2. A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur before the start of treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Subjects taking prohibited medications as described in Section 6.3.2.",
                        "criterion": "use of prohibited medications",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur before the start of treatment.",
                        "criterion": "washout period for prohibited medications",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur before the start of treatment.",
                        "criterion": "washout period for prohibited medications",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "before the start of treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Subjects taking prohibited medications as described in Section 6.3.2.",
                                "criterion": "use of prohibited medications",
                                "requirement": {
                                    "requirement_type": "absence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur before the start of treatment.",
                                "criterion": "washout period for prohibited medications",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur before the start of treatment.",
                                "criterion": "washout period for prohibited medications",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "before the start of treatment"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Subjects taking prohibited medications as described in Section 6.3.2.",
                        "criterion": "use of prohibited medications",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with muscular and/or neuromuscular disorders associated with elevated CPK (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, or spinal muscular atrophy).",
                "criterions": [
                    {
                        "exact_snippets": "muscular and/or neuromuscular disorders",
                        "criterion": "muscular or neuromuscular disorder",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "associated with elevated CPK",
                        "criterion": "creatine phosphokinase (CPK) level",
                        "requirement": {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, or spinal muscular atrophy",
                        "criterion": "specific neuromuscular disorders",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "inflammatory myopathies",
                                "muscular dystrophy",
                                "amyotrophic lateral sclerosis",
                                "spinal muscular atrophy"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "--Note: Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.",
                "criterions": [
                    {
                        "exact_snippets": "past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg)",
                        "criterion": "HBV infection status",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": [
                                "past",
                                "resolved"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg)",
                        "criterion": "HBV infection status",
                        "requirement": {
                            "requirement_type": "anti-HBc presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg)",
                        "criterion": "HBV infection status",
                        "requirement": {
                            "requirement_type": "HBsAg presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA",
                        "criterion": "HCV infection status",
                        "requirement": {
                            "requirement_type": "HCV antibody presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA",
                        "criterion": "HCV infection status",
                        "requirement": {
                            "requirement_type": "HCV RNA (PCR) result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}